Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Syndax Pharmaceuticals, Inc is a biotechnology business based in the US. Syndax Pharmaceuticals shares (SNDX) are listed on the NASDAQ and all prices are listed in US Dollars. Syndax Pharmaceuticals employs 35 staff and has a trailing 12-month revenue of around USD$1.5 million.
|Latest market close||USD$25.75|
|52-week range||USD$6.32 - USD$23.98|
|50-day moving average||USD$19.52|
|200-day moving average||USD$16.6628|
|Wall St. target price||USD$24.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.357|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||N/A|
|1 month (2020-12-22)||7.25%|
|3 months (2020-10-18)||N/A|
|6 months (2020-07-18)||N/A|
|1 year (2020-01-18)||N/A|
|2 years (2019-01-18)||N/A|
|3 years (2018-01-18)||N/A|
|5 years (2016-01-18)||N/A|
|Revenue TTM||USD$1.5 million|
|Gross profit TTM||USD$1.5 million|
|Return on assets TTM||-32.15%|
|Return on equity TTM||-75.83%|
|Market capitalisation||USD$902 million|
TTM: trailing 12 months
There are currently 4.6 million Syndax Pharmaceuticals shares held short by investors – that's known as Syndax Pharmaceuticals's "short interest". This figure is 5.1% up from 4.4 million last month.
There are a few different ways that this level of interest in shorting Syndax Pharmaceuticals shares can be evaluated.
Syndax Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Syndax Pharmaceuticals shares currently shorted divided by the average quantity of Syndax Pharmaceuticals shares traded daily (recently around 748421.46341463). Syndax Pharmaceuticals's SIR currently stands at 6.15. In other words for every 100,000 Syndax Pharmaceuticals shares traded daily on the market, roughly 6150 shares are currently held short.
However Syndax Pharmaceuticals's short interest can also be evaluated against the total number of Syndax Pharmaceuticals shares, or, against the total number of tradable Syndax Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Syndax Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Syndax Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1237% of the tradable shares (for every 100,000 tradable Syndax Pharmaceuticals shares, roughly 124 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Syndax Pharmaceuticals.
Find out more about how you can short Syndax Pharmaceuticals stock.
We're not expecting Syndax Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Syndax Pharmaceuticals's shares have ranged in value from as little as $6.32 up to $23.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syndax Pharmaceuticals's is 1.6984. This would suggest that Syndax Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Everything we know about the NLS Pharmaceutics Ltd IPO, plus information on how to buy in.
Everything we know about the GitLab IPO, plus information on how to buy in.
Everything we know about the Longeveron LLC IPO, plus information on how to buy in.
Everything we know about the Signify Health Inc IPO, plus information on how to buy in.
Everything we know about the Biophytis SA IPO, plus information on how to buy in.
Everything we know about the NexImmune Inc IPO, plus information on how to buy in.
Everything we know about the Adagene Inc IPO, plus information on how to buy in.
Everything we know about the Cloopen Group Holding Limited IPO, plus information on how to buy in.
Everything we know about the Decipher Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Proterra IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.